Ocular Therapeutix: Promising Pipeline and Strategic Developments Justify Buy Rating Despite Current Financial Challenges

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Ocular Therapeutix (OCUL – Research Report). The associated price target remains the same with $15.00.

Yi Chen’s rating is based on several key factors. Despite Ocular Therapeutix’s recent financial results showing a decline in revenue and a higher net loss than expected, the company has promising developments in its pipeline. The management anticipates an increase in net product revenue for DEXTENZA throughout 2025, driven by adjustments to the Centers for Medicare & Medicaid Services’ Merit-based Incentive Payment System. Additionally, the Phase 3 SOL-1 trial for AXPAXLI in wet AMD is progressing well, with exceptional retention and topline data expected in the first quarter of 2026.
Furthermore, the incorporation of re-dosing in the SOL-1 trial could accelerate the path to a new drug application submission, potentially supporting a dosing label of every 6-12 months. The ongoing SOL-R trial is robustly powered, and the company has received positive feedback from the FDA regarding a potential registrational trial for AXPAXLI in non-proliferative diabetic retinopathy. These factors contribute to the confidence in Ocular Therapeutix’s future prospects, justifying the Buy rating and a price target of $15.

According to TipRanks, Chen is an analyst with an average return of -15.2% and a 30.14% success rate. Chen covers the Healthcare sector, focusing on stocks such as Opko Health, OKYO Pharma Limited Sponsored ADR, and Vivani Medical.

In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $14.00 price target.